Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 5/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | NOS1 | P29475 | 4/20 | 0.46 |
| ▸ | NOS3 | P29474 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 5/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.45 |
| ▸ | CDK1 | P06493 | 3/20 | 0.44 |
| ▸ | CDK4 | P11802 | 2/20 | 0.44 |
| ▸ | CCND1 | P24385 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22199287 | 0.90 | HDAC1 (0.45) | NOS2HDAC1NOS1NOS3CDK2 | |
| SCHEMBL16048538 | 0.89 | HDAC3 (0.49) | HDAC1CDK2CDK1CDK4CCND1 | |
| SCHEMBL17832692 | 0.83 | P2RY12 (0.49) | NOS2HDAC1CDK2CDK1CDK4 | |
| SCHEMBL17830863 | 0.83 | HDAC1 (0.44) | HDAC1CDK2CDK1CDK4CCND1 | |
| SCHEMBL17762744 | 0.83 | MAPT (0.53) | NOS2NOS1NOS3CDK2CDK1 | |
| SCHEMBL17832701 | 0.81 | HDAC1 (0.55) | HDAC1CDK2CCNA2CCNA1CDK1 | |
| SCHEMBL20564983 | 0.80 | ENPP2 (0.49) | — | |
| SCHEMBL30807478 | 0.80 | ENPP2 (0.49) | — | |
| SCHEMBL12723444 | 0.80 | ACACB (0.40) | — | |
| SCHEMBL22092814 | 0.78 | PCSK9 (0.43) | HDAC1HDAC3HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348389-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348389-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11702389-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702389-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210179559-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2021-06-17 | — | — | US | disclosed |
| US-10968180-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-10358421-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2019-07-23 | — | — | US | disclosed |
| US-10239837-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180022702-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | ACETYLON PHARMACEUTICALS, INC. | 2018-01-25 | — | — | US | disclosed |
| US-9790180-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160168093-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168093-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | NOS2 1395/4885HDAC1 1/4885NOS1 2145/4885 |
| US-20210179559-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | NOS2 1395/4885HDAC1 1/4885NOS1 2145/4885 |
| US-11702389-B2 | Piperidine derivatives as HDAC1/2 inhibitors | HDAC1, HDAC2, HDAC10 | NOS2 1395/4885HDAC1 1/4885NOS1 2145/4885 |
| US-20230348389-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | NOS2 1395/4885HDAC1 1/4885NOS1 2145/4885 |
| US-10968180-B2 | Piperidine derivatives as HDAC1/2 inhibitors | HDAC1, HDAC2, HDAC10 | NOS2 1395/4885HDAC1 1/4885NOS1 2145/4885 |
| US-10239837-B2 | Piperidine derivatives as HDAC1/2 inhibitors | HDAC1, HDAC2, HDAC10 | NOS2 1395/4885HDAC1 1/4885NOS1 2145/4885 |
| US-10358421-B2 | Piperidine derivatives as HDAC1/2 inhibitors | HDAC1, HDAC2, HDAC10 | NOS2 1395/4885HDAC1 1/4885NOS1 2145/4885 |
| US-20180022702-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | NOS2 1395/4885HDAC1 1/4885NOS1 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.